Belcher Pharmaceuticals LLC., Largo, FL
Is Belcher Pharmaceuticals LLC. registered with the FDA as a 503B outsourcing facility?
No matching record found in FDA’s registered outsourcing facility list (updated Nov 6, 2026) on Nov 15, 2026, searching by name and location. FDA’s compounding inspections and actions page labels its entry 503B, with FDA’s note “De-registered as an outsourcing facility”.
Does Belcher Pharmaceuticals LLC. hold a Florida pharmacy license?
No license with this exact name and city was found in the Florida Board of Pharmacy file dated Nov 15, 2026. A pharmacy can hold its license under a different legal name, so this is not a finding that it is unlicensed. The file covers pharmacy permits at Florida addresses.
Has Belcher Pharmaceuticals LLC. had a state board action or FDA letter?
FDA letters: record found. FDA’s compounding inspections and actions page, current as of Oct 22, 2026, lists 1 FMD-145 letter (Jan 29, 2025) for Belcher Pharmaceuticals LLC. State board actions: no Florida Board of Pharmacy action under this exact name and city was found in the board’s enforcement list for pharmacy permits (actions dated Sep 19, 1980 to Nov 10, 2026) on Nov 15, 2026.
FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.
- Names in FDA records
- Belcher Pharmaceuticals LLC.
- Location
- Largo, FL
- Type as FDA labels it
- 503B
- FDA’s note
- De-registered as an outsourcing facility
- FDA 503B list
- No matching record found
- Form 483s on FDA’s actions page
- 1
- Warning letters on FDA’s actions page
- 0
- Latest action on that page
- Jan 29, 2025
- FDA Data Dashboard inspections
- No matching site found
- Form 483 text on this page
- 1 Form 483, 6 observations
- State board records
- No exact match
FDA inspections and letters
FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as Belcher Pharmaceuticals LLC., a 503B facility, with 2 dated actions.
| Document | |||
|---|---|---|---|
| Jan 29, 2025 | FMD-145 letter | FMD-145 Letter Issued 01/29/2025 | Not linked by FDA |
| Aug 16, 2024 | Form 483 | 483 Issued 08/16/2024 | FDA copy (archived) |
A Form 483 lists investigator observations, not a final FDA determination. An untitled or FMD-145 letter states FDA’s view when it was issued.
FDA inspection classifications and published Form 483s
No inspected site under this exact name and city was found in the FDA Data Dashboard on Nov 15, 2026, searching 12,593 US sites with a drug inspection ending Oct 1, 2008 to Oct 23, 2026. FDA may list the site under another legal name, so this is not a finding that it was never inspected.
Form 483 observations
A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.
FDA’s published Form 483 for this site has 6 numbered observations in all. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.
Inspection Aug 7, 2024 to Aug 16, 2024: 6 observations
- Firm on the cover
- Belcher Pharmaceuticals, LLC, 12393 Belcher Rd S Ste 420, Largo, FL 33773-3097
- FEI number
- 1000526113
- Establishment type on the cover
- 503B Outsourcing Facility
- FDA district office on the cover
- 555 Winderley Place, Suite 200 Maitland, FL 32751
- Matched to this page by
- firm name, city and state on the cover; linked from actions page
- FDA document
- Read the full 483 (Internet Archive copy FDA links)
Observation 1
Each batch of controlled-release dosage form drug product is not laboratory tested to detemiine conformance to the specifications for the rate of release for each active ingredient.
Specifically, your fnm failed to conduct dissolution testing as part of your finished product specification requirements prior to batch release for all strengths of Testosterone pellets (12.5mg, 37.5mg, 50mg, 100mg and 225mg) therefore your firm is unable to ensure the pellets do not dissolve immediately, remain integral ( does not cmmble or break into pieces) and release API at a rate that is reproducible.
The following batches were released for distribution: Testosterone Pellets 100mg, lot <Redacted B4>, CPD:9/6/23 BUD: 9/4/24 (QTYj <Redacted B4> blister packs <Redacted B4> pellets) Testosterone Pellets 37.5mg, lot <Redacted B4> CPD: 2/19/24, BUD: 2/12/25 (t>j (blister packs} <Redacted B4> (phllets), ;testosterone Pellets, 50mg lot <Redacted b4> CPD: 2/19/24 BUD: 2/12/25 <Redacted B4> blister packs t:5) ( <Redacted B4> pellets) and Testosterone Pellets, 100mg lot <Redacted B4>, CPD: 2 19 24, BUD: 2/12/25 <Redacted B4> blister packs - <Redacted B4> pellets).
Observation 2
Each batch of drug product required to be free of objectionable niicroorganisms is not tested through appropriate laboratory testing. testing and are still observed at the 14-day inspection for growth therefore illustrating the interior position of the pellet is not being tested.
Specifically, your firm's control testing lab utilizes the Sterility Testing Method (STM No. M109) which is inadequate as it only accounts for the testing of the exterior position of the pellets by direct inoculation rather than crushing the pellets or requiring them to dissolve prior to testing. In addition, your control testing labs, Assistance Microbiology Manager, stated that the pellets do not dissolve completely during testing and are still observed at the 14-day inspection for growth therefore illustrating the interior portion of the pellet is not being tested.
testing and are still observed at the 14-day inspection for growth therefore illustrating the interior po1iion of the pellet is not being tested. ...
Observation 3
Laboratory controls do not include the establishment of scientifically sound and appropriate specifications and test procedures designed to assm·e that drug products conform to appropriate standards of identity, strength, quality and purityy
Specifically, your firm failed to conduct testing for impurities as part of your finished product specification requirements prior to batch release for all strengths of Testosterone pellets (12.5mg, 37.5mg, 50mg, 100mg and 225mg) therefore your firm is unable to ensure degradants such as Androstenedione (Androst-4-ene-3,17-dione), unknown and unspecified related substances can be detected.
The following batches were released for distribution: Testosterone Pellets 100mg, lot # <Redacted B4>, CPD:9/6/23, BUD: 9/4/24 (QTY <Redacted B4> blister packs) <Redacted B4> pellets , Testosterone Pellets 37.5mg, lot <Redacted B4> CPD: 2/19/24, BUD: 2/12/25 <Redacted B4> blister packs <Redacted B4> pellets Testosterone Pellets, 50mg lot <Redacted B4> CPD: 2/19/24 BUD: 2/12/25 <Redacted B4> blister packs <Redacted B4> pellets) and Testosterone Pellets, 100mg lot <Redacted B4> CPD: 2 19 24, BUD: 2/12/25 <Redacted B4> blister packs <Redacted B4> pellets).
Observation 4
Specifically, your firm failed to certify the following production rooms: Room <Redacted B4>, Room <Redacted B4> Room <Redacted B4>, Room <Redacted B4> and Room <Redacted B4> where <Redacted B4> sterilized (via <Redacted B4> Testosterone Pellets (12.5mg, 37.5mg, 50mg, I00mg and 225mg) are produced under ISO-8 or better air quality as determined under dynamic conditions. In addition, air exchanges conducted <Redacted B4> for the production rooms do not meet ISO 8 D Specifications, non-viable particle counts and HEPA filter integrity testing are only performed every □rather than bi-annually.
Observation 5
The labels of your outsourcing facility's drug products do not include information required by section 503B(a)(IO)(A) ofthe Federal Food, Drug and Cosmetic Act (FD&C Act).
Specifically, the following information is not found on your drug product labels:
a) The statement "This is a compounded drug";
b) The phone number of the outsourcing facility;
c) The storage and handling instructions;
Examples of your drug product labels that do not contain this information: Testosterone Pellets 37.5mg Testosterone Pellets 50mg Testosterone Pellets I00mg Testosterone Pellets 225mg
Observation 6
Your outsourcing facility has not submitted a report to FDA identifying a product compollllded during the previous six months as required by section 503B(b )(2)(A) ofthe Federal Food, Dmg, and Cosmetic Act (FD&C Act).
Specifically, the following product was compounded and not identified on your report dated December 2023 (2023-2). Testosterone Pellets, I 00mg
State board of pharmacy records
No license with this exact name and city was found in the Florida Board of Pharmacy file dated Nov 15, 2026. A pharmacy can hold its license under a different legal name, so this is not a finding that it is unlicensed. The file covers pharmacy permits at Florida addresses. Board file.
What this covers: Every enforcement action the Florida Department of Health lists for Board of Pharmacy pharmacy permits, worded as the department gives it. The list includes administrative complaints filed as well as final actions, and links no documents. An administrative complaint is an allegation the department has filed, not a finding. Actions in the data are dated Sep 19, 1980 to Nov 10, 2026.
This page restates FDA’s lists and state board of pharmacy records. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.
Sources
- FDA: Compounding: Inspections, Recalls, and other Actions
- FDA Registered Outsourcing Facilities (503B)
- FDA Data Dashboard: inspection classifications and published Form 483s
- FDA: FDA Form 483 Frequently Asked Questions
- Florida Board of Pharmacy license file
- Florida Board of Pharmacy disciplinary records
Records last pulled Nov 15, 2026. Every entry links to the original public record.